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Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory 
disease (AID) affecting mainly the ethnic groups originating from Mediterranean basin. 
The disease is characterized by self-limited inflammatory attacks of fever and polysero-
sitis along with elevated acute phase reactants. FMF is inherited autosomal recessively; 
however, a significant proportion of heterozygotes also express the phenotype. FMF 
is caused by mutations in the MEFV gene coding for pyrin, which is a component of 
inflammasome functioning in inflammatory response and production of interleukin-1β 
(IL-1β). Recent studies have shown that pyrin recognizes bacterial modifications in Rho 
GTPases, which results in inflammasome activation and increase in IL-1β. Pyrin does not 
directly recognize Rho modification but probably affected by Rho effector kinase, which 
is a downstream event in the actin cytoskeleton pathway. Recently, an international group 
of experts has published the recommendations for the management of FMF. Colchicine 
is the mainstay of FMF treatment, and its regular use prevents attacks and controls 
subclinical inflammation in the majority of patients. Furthermore, it decreases the long-
term risk of amyloidosis. However, a minority of FMF patients fail to response or tolerate 
colchicine treatment. Anti-interleukin-1 drugs could be considered in these patients. One 
should keep in mind the possibility of non-compliance in colchicine-non-responders. 
Although FMF is a relatively well-described AID and almost 20 years has passed since 
the discovery of the MEFV gene, there are still a number of unsolved problems about 
it such as the exact mechanism of the disease, symptomatic heterozygotes and their 
treatment, and the optimal management of colchicine resistance.
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iNTRODUCTiON
Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease 
(AID) over the world. Its prevalence is very high among people from the eastern Mediterranean 
such as Jews, Turks, Armenians, and Arabs (1, 2). However, patients from different ethnicities (such 
as Japan) are being increasingly recognized (3, 4). Self-limited inflammatory attacks of fever and 
polyserositis along with high acute phase response are the typical phenotype expected in FMF 
(5). The most significant complication of FMF is amyloidosis, and it is responsible for long-term 
Table 1 | Recommendations for familial Mediterranean fever (FMF) 
genetic diagnosis [adapted from Ref. (8)].
Recommendation Strength of 
evidence
1. FMF is a clinical diagnosis, which can be supported but not 
excluded by genetic testing
B
2. Consider patients homozygous for M694V at risk of 
developing, with very high probability, a severe phenotype
B
3. FMF patients carrying two of the common mutated alleles 
(homozygotes or compound heterozygotes), especially for 
M694V mutation or mutations at position 680–694 on exon 10, 
must be considered at risk of having a more severe disease
B
4. The E148Q variant is common, of unknown pathogenic 
significance, and as the only MEFV variant does not support 
the diagnosis of FMF
B
5. Patients homozygous for M694V mutation are at risk of early 
onset disease
C
6. Individuals homozygous for M694V who are not reporting 
symptoms should be evaluated and followed closely in order to 
consider therapy
A
7. For individuals with two pathogenic mutations for FMF 
who do not report symptoms, if there are risk factors for 
AA amyloidosis (such as the country, family history, and 
persistently elevated inflammatory markers, particularly serum 
amyloid A protein), close follow-up should be started and 
treatment considered
B
8. Consultation with an autoinflammatory disease specialist may 
be helpful in order to aid in the indication and interpretation of 
the genetic testing and diagnosis
C
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morbidity and mortality (6). Although it is known to be inherited 
autosomal recessively, a substantial number of heterozygotes are 
present expressing the phenotypic characteristics (7).
Since the definition of MEFV gene mutations underlying FMF 
in 1997, around 310 sequence variants in MEFV gene have been 
detected (8). MEFV gene, located on chromosome 16 encodes 
for pyrin protein (9, 10). Pyrin, exists mostly in neutrophils 
and macrophages, has a key role in apoptosis and inflammatory 
pathways (9, 11). Mutated pyrin causes an exaggerated inflamma-
tory response by uncontrolled interleukin-1 (IL-1) secretion (11). 
Recent studies have supplied information about the importance 
of the role of pyrin as a pattern recognition receptor (PRR), as 
well (12).
Colchicine is the mainstay of FMF treatment, and its regular 
use prevents attacks and suppresses chronic subclinical inflam-
mation (13–15). Anti-IL-1 drugs emerged as promising treatment 
options in patients who fail to response or tolerate colchicine. 
Compliance to this orally administered drug is a problem. 
In resistant cases, the clinicians should also keep in mind whether 
the patient is compliant to the therapy (16). Recently, a group 
of international experts has published the recommendations for 
the management of FMF to guide physicians taking care of these 
patients (17).
In this review, we will discuss the new findings in the patho-
genesis of FMF and the new recommendations for management.
GeNeTiCS OF FMF
In 1997, mutations in the MEFV gene, composed of 10 exons 
and located on chromosome 16 (16p13.3), were found to be 
associated with FMF (9, 10, 18). The gene encodes a 781 amino 
acid protein termed pyrin or marenostrin (9, 10, 18). Only a few 
mutations had been defined in selected families when the genetic 
association was first described (10, 19). Up to date, according to 
the INFEVERS database, more than 310 MEFV sequence variants 
have been reported (http://fmf.igh.cnrs.fr/infevers/). However, 
all variants are not associated with a disease phenotype and are 
termed “variants of uncertain significance.” With the description 
of new mutations, concerns emerged for the adequacy of check-
ing only the common mutations. Booty et  al. sequenced the 
MEFV gene in FMF patients and showed that screening the most 
common mutations instead of sequencing the whole gene appears 
sufficient to diagnose FMF in presence of clinical symptoms (20). 
In 2012, a group of clinical and molecular experts reached a 
consensus to test for a total of 14 MEFV variants if possible (21). 
These include nine clearly pathogenic variants (M694V, M694I, 
M680I, V726A, R761H, A744S, I692del, E167D, and T267I) and 
five variants of unknown significance (E148Q, K695R, P369S, 
F479L, and I591T) (21).
In the Eastern Mediterranean, the distribution of MEFV 
mutations is quite similar. M694V is the most common mutation 
in Turk (5), Armenian (22, 23), Arab (24), and Jewish popula-
tions (25); however, it is less common in Arabs (26). The second 
most common mutation is M680I in Turks (5); and V726A in 
Armenians (22, 23), Arabs (24), and Jews (25). M680I is the third 
most common mutation in Armenians (23). M694I is mostly seen 
in the Arabic population (24). On the other hand, in populations 
where FMF is a rare disease, the aforementioned mutations are 
less common, and other mutations are also seen. For example, in 
Japanese patients, E148Q is the most common variant followed 
by M694I and L110P (3). The clinical variability in FMF could 
be partly explained by genetic heterogeneity. For instance, most 
experts agreed that M694V was associated with a severe disease 
phenotype (8).
Recently, evidence-based recommendations have been devel-
oped for genetic diagnosis of FMF by the Single Hub and Access 
point for pediatric Rheumatology in Europe (SHARE) initiative 
(8). These recommendations are presented in Table 1. According 
to these, patients homozygous for M694V should be considered 
at higher risk of early disease onset and developing a severe 
phenotype (8). Furthermore, the patients carrying two mutated 
alleles in position 680–694 on exon 10 are also considered at risk 
of having a more severe disease (8).
Another area of debate is E148Q variant. E148Q, the most 
frequent sequence alteration in the MEFV gene (27), is the result 
of the substitution of glutamine for glutamic acid at codon 148 in 
exon 2 (28, 29). E148Q is a common variant in the general popula-
tion; however, the pathogenic role of E148Q is still uncertain (30).
In 2000, in a case–control study, Ben-Chetrit et  al. found a 
similar frequency for E148Q mutation both in patients and 
healthy controls and in patients and their asymptomatic relatives 
(27). Tchernitchko et  al. also demonstrated that E148Q allele 
frequency was comparable among patients and asymptomatic 
relatives and they concluded E148Q as a benign polymorphism 
(31). However, other studies (32, 33) showed that patients with 
homozygous E148Q variant might have an FMF-like phenotype 
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requiring colchicine treatment. In a recent study, it has been sug-
gested that the disease was less severe, the disease onset was later, 
and the ratio of patients responding completely to colchicine was 
higher in—at least a portion of—patients homozygous for E148Q 
when compared to the patients with exon 10 mutations (34).
Shinar et  al. defined E148Q as a variant of unknown sig-
nificance (21) and according to the SHARE recommendations, 
E148Q, as the only MEFV variant, does not support the diagnosis 
of FMF (8).
Although FMF is considered as an autosomal recessive disease, 
it was recognized that a significant portion of the patients had 
only one mutation in the MEFV gene (25, 35). Marek-Yagel et al. 
examined heterozygote FMF patients and performed haplotype 
studies in FMF families (36). They concluded that in some cases, 
the disease in heterozygotes could not be distinguished from that 
of homozygous patients, and FMF could be viewed as a dominant 
condition with low penetrance. Booty et al. searched for a second 
MEFV mutation in heterozygote patients who had a clinical 
diagnosis of FMF (20). However, re-sequencing the entire MEFV 
gene did not yield a second mutation in any of these cases (20). A 
recent study demonstrated that the frequency of FMF-like symp-
toms increased from patients carrying a single low penetrance 
mutation toward patients with two high-penetrance mutations 
suggesting a “dose effect” associated with mutations (37). One 
other explanation for heterozygote FMF patients may be the effect 
of the other modifier genes such as serum amyloid A (SAA) gene. 
SAA polymorphisms have been shown to contribute the severity 
of FMF phenotype inducing the expression of pro-interleukin-
1β (IL-1β) and activating NLRP3 inflammasome resulting in 
the secretion of active IL-1β (4, 38). In the same lines, recently, 
Atoyan et al. have shown that SAA1 α allele was strongly associ-
ated with amyloidosis in FMF patients (39). On the other hand, 
environmental factors also have effect on the disease phenotype. 
Touitou et al. examined the characteristics of 2,482 FMF patients 
(260 of whom had amyloidosis) from 14 different countries (40). 
They demonstrated that the country of recruitment (roughly 
the same as the country of residence) was the most important 
determinant of amyloidosis risk.
We had shown that Turkish children with FMF in Germany 
expressed a less severe disease phenotype in comparison with 
the ones living in eastern Mediterranean (41). In addition, when 
we examined the Eurofever registry, we have seen that patients 
with a European ancestry have a milder disease than the Eastern 
Mediterranean patients (41). Furthermore, patients living in 
eastern Mediterranean countries had a higher frequency of fever 
episodes per year, and more frequent arthritis, pericarditis, chest 
pain, abdominal pain, and vomiting compared to the patients 
living in Western Europe (41). It was noteworthy that Western 
European patients had less frequent abdominal pain, pericarditis, 
and arthritis than eastern Mediterraneans (41). All of the above 
studies suggest the effect of environment on the phenotype of this 
monogenic disease.
Another issue that deserves a mention is autosomal dominant 
FMF. Different mutations (H478Y, T577S, T577A, T577N, M694del, 
M694I, E148Q, and L110P) in MEFV have been reported to cause 
dominant FMF in patients from different populations; Spanish, 
Turkish, Dutch, British, Indian, and Japanese (18, 41–45). These 
reports have shown that FMF could also be inherited autosomal 
dominantly, and these patients may have different disease phe-
notypes. Rowczenio et al. reported that symptoms may develop 
later in life in autosomal dominant FMF with p.M694Vdel than in 
classical recessive FMF (45). Stoffels et al. have demonstrated that 
these patients may have different symptoms during attacks such as 
urticarial rash and conjunctivitis overlapping with other AID (18).
Although this is a monogenic disease, epigenetic factors and 
microbiota may play role in the pathogenesis of FMF or pheno-
typic expression. It is tempting to speculate that host–microbe 
interactions may be important in this innate immune system 
disease. Khachatryan et  al. demonstrated that the composition 
and divergence of microbiota were different during attack and 
attack-free periods as well as between FMF patients and healthy 
controls (46).
DiSeaSe PaTHOGeNeSiS
Pyrin, encoded by MEFV, has been suggested to interact with ASC 
(the inflammasome adaptor protein). The subsequent assembly of 
the inflammasome was suggested to activate caspase-1 leading to 
the cleavage and activation of IL-1β (47).
Until recently, it was a debate whether the disease-causing 
mutations in the MEFV gene were loss-of-function or gain-of-
function mutations. There were different results depending on the 
different experimental settings. Supporting the loss-of-function 
model, Papin et al. demonstrated an increase in caspase-1 activa-
tion and IL-1β secretion as a result of pyrin knockdown (48). 
Hesker et al. showed that in response to inflammatory stimuli in a 
mouse line lacking the MEFV gene, IL-1β release by macrophages 
was enhanced (49).
On the other hand, in compliance with the gain-of-function 
model, Booty et al. demonstrated a significant increase in pyrin 
expression in FMF patients compared to healthy controls (20). 
Yu et  al. have shown that activated pyrin forms a trimolecular 
complex by interacting with ASC and PTSPIP1, and this complex 
directly activates caspase-1 and leads to secretion of IL-1β (50). In 
2011, Chae et al. have demonstrated that homozygous knock-in 
mice with the mouse pyrin protein fused to the human B30.2 
domain containing FMF-associated mutations secrete large 
amounts of IL-1β in an NLRP3-independent manner (51). These 
data confirmed that the mutations associated with FMF were 
gain-of-function mutations and suggested that FMF was a pyrin 
inflammasomopathy (51).
Almost 20 years after defining the genetic basis of FMF and 
learning the role of pyrin in its pathogenesis, we now have some 
new data elaborating the role of pyrin in pathogenesis (12, 52). 
The detection of pathogenic microorganisms by PRRs triggers the 
formation of inflammasome (53). Recent data suggest that pyrin 
is also a PRR (12).
Two major virulence factors of Clostridium difficile, namely, 
TcdA and TcdB (54, 55) inactivate Rho GTPases via monogly-
cosylating a threonine residue in the GTPase switch I region of 
the protein (12). Recent studies have also shown that TcdB could 
trigger caspase-1 activation and IL-1β production; thus, it can 
activate the inflammasome (12, 56, 57). Furthermore, the C3 
toxin of Clostridium botulinum and type VI secretion system 
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(T6SS) of Burkholderia cenocepacia inactivate RHO by modifying 
the GTPase switch I region with different chemical groups and 
both trigger inflammasome activation (12). These results suggest 
that the bacterial toxins modifying RHO could trigger caspase-1 
activation and IL-1β production; thus induce the inflammasome 
(12). The inflammasome activation by these toxins (TcdB, C3, 
and T6SS) was independent of NLRP3 and NLRC4 but was 
decreased in ASC−/− and MEFV−/− bone marrow-derived mac-
rophages (12). In addition, small interference RNA knockdown 
of pyrin inhibited TcdB-induced caspase-1 activation (12). These 
results also support the “gain-of-function” model in the patho-
genesis of FMF. Since different inhibiting modifications in RHO 
proteins all result in caspase-1 activation, pyrin probably senses a 
downstream event in the actin cytoskeleton pathway (12).
The study by Park et  al. has enlightened these mechanisms 
further (52). They have demonstrated that staurosporine, a potent 
inhibitor of protein kinase C that is an effector of RhoA, induced 
IL-1β release independent of the NLRP3, NLRC4, or AIM2 
inflammasomes but dependent on the pyrin inflammasome (52). 
This shows that RhoA effector kinases suppress pyrin inflamma-
some activation. PKNs, RhoA effector kinases, bind to human 
pyrin and phosphorylate Ser208 and Ser242 units. The binding of 
PKN1 to the pyrin of FMF-knock-in mice (with B30.2 mutations; 
MefvM680I/M680I, MefvM694V/M694V, and MefvV726A/V726A) was substan-
tially decreased in comparison with the binding of PKN1 to wild 
type (Mefv+/+) mouse pyrin, which lacks a B30.2 orthologous 
domain (52). The binding of PKN1 to the pyrin of wild type B30.2 
domain knock-in mice (MefvB30.2/B30.2) was also decreased relative 
to wild-type mouse pyrin (but not as much as in FMF knock-in 
mice) (52). These suggest that the human B30.2 domain has a role 
in the regulation of PKN1 binding to pyrin. It was also shown 
that 14-3-3 protein binds to phospho-pyrin (phosphorylated 
from Ser208 and Ser242 units by PKNs) to inhibit inflammasome 
activation. Furthermore, the binding of 14-3-3 to mutant pyrin 
(M680I, M694V, and V726A) was decreased relative to wild-type 
human pyrin (52). All aforementioned results show that active 
RhoA signals through PKNs, which phosphorylate pyrin from 
Ser208 and Ser242 units. Then, 14-3-3 proteins bind to phospho-
pyrin and inhibit the activation of pyrin inflammasome. Pyrin is 
activated when dephosphorylated at Ser208/Ser242. The binding 
of PKN1 to pyrin is decreased with the B30.2 domain where most 
of the common and severe MEFV mutations are clustered.
These data enlighten the effect of mutations on pyrin function 
and the downstream event of RhoA inhibiting pyrin. Active pyrin 
promotes ASC oligomerization and forms a caspase-1 activat-
ing complex resulting in IL-1β production. Wild-type pyrin 
relies selectively on microtubules for inflammasome activation 
and microtubules control pyrin signaling downstream of pyrin 
dephosphorylation (52). Recently, Van Gorp et al. have observed 
that colchicine pretreatment augments the TcdA-induced IL-1β 
secretion from FMF peripheral blood mononuclear cells (58). 
The microtubule assembly inhibition with nocodazole also had 
the same effect. Thus, FMF-associated mutated pyrin does not 
require microtubules for ASC speck assembly. MEFV mutations 
in B30.2 domain probably remove the critical reliance on intact 
microtubules for pyrin-based nucleation of ASC specks and 
inflammasome signaling (58).
To make the story even more complex, in a recent study, 
Kimura et al. have demonstrated that pyrin (referred as TRIM20 
in the article) recognizes the inflammasome components, 
NLRP1, NLRP3, and procaspase-1 and leads to their autophagic 
degradation (59). Diminished autophagic degradation of NLRP3 
was shown in single (M694V), double (M680I and M694V), and 
triple (M680I, M694V, and V726A) mutants (59).
When we look at the cellular level, we know that neutrophilia 
and influx of neutrophils to the inflamed sites occur in FMF 
attacks (60). Gohar et  al. demonstrated that in  vitro, unstimu-
lated neutrophils from M694V positive patients spontaneously 
secreted more S100A12, IL-18, and caspase-1 compared to 
neutrophils from healthy controls (61). In another study, it has 
recently been shown that FMF attack is characterized by release 
of neutrophil extracellular traps (NET) including active IL-1β 
(60). These NET structures are observed in the first hours of FMF 
attacks, and subside as the inflammatory attack is resolved. They 
have demonstrated that NETs restrict their own generation by 
a negative feedback mechanism, which may be an explanation 
for the self-limited nature of FMF attacks. Of note, in this study, 
neutrophils from FMF patients in remission were resistant to 
induction of NET release. They have shown that reduced basal 
autophagy levels in these cells could be responsible for this since 
autophagy induction is needed for NET formation. Thus, lower 
basal autophagy levels of neutrophils may protect from attacks by 
attenuating the release of pro-inflammatory NETs.
Manukyan et al. have recently shown that the ex vivo spontane-
ous apoptotic rate of neutrophils from FMF patients in remission 
is significantly higher compared to control (62). The accelerated 
apoptosis of neutrophils in FMF may be important for successful 
resolution of inflammation and prevention of tissue damage. This 
may be another explanation for the self-limited nature of FMF 
attacks. Pyrin modulates the susceptibility to apoptosis; however, 
the effect of the mutant pyrin on apoptotic processes is poorly 
understood.
Although now we know more about the function of pyrin, the 
role of neutrophils, and the disease pathogenesis, there are still 
questions waiting to be answered such as the exact reason for the 
episodic and short-term nature of the inflammatory attacks and 
the phenotypic variability in FMF.
TReaTMeNT
Familial Mediterranean fever can be well controlled with opti-
mum standard management. Recently, with the international 
collaboration of experienced experts from different countries, the 
European League Against Rheumatism (EULAR) recommenda-
tion set for the management of FMF has been published supported 
by the best available evidence (17). These recommendations are 
presented in Table 2.
The EULAR recommendations emphasize that the aim of FMF 
treatment is obtaining the control of acute attacks, minimizing 
the chronic and subclinical inflammation, preventing complica-
tions, and providing an acceptable quality of life.
It is also emphasized that colchicine is the main treatment of 
FMF since 1972 (63). It is generally a safe and well-tolerated drug, 
but its mechanism of action in FMF has not been completely 
Table 2 | The european league against Rheumatism recommendations 
for the management of FMF with grade of recommendation [adapted 
from Ref. (17)].
Recommendation Grade
01. Ideally, FMF should be diagnosed and initially treated by a physician 
with experience in FMF
D
02. The ultimate goal of treatment in FMF is to reach complete control 
of unprovoked attacks and minimizing subclinical inflammation in 
between attacks
C
03. Treatment with colchicine should start as soon as a clinical 
diagnosis is made
A
04. Dosing can be in single or divided doses, depending on tolerance 
and compliance
D
05. The persistence of attacks or of subclinical inflammation represents 
an indication to increase the colchicine dose
C
06. Compliant patients not responding to the maximum tolerated 
dose of colchicine can be considered non-respondent or resistant; 
alternative biological treatments are indicated in these patients
B
07. FMF treatment needs to be intensified in AA amyloidosis using 
the maximal tolerated dose of colchicine and supplemented with 
biologics as required
C
08. Periods of physical or emotional stress can trigger FMF attacks, and 
it may be appropriate to increase the dose of colchicine temporarily
D
09. Response, toxicity, and compliance should be monitored every 
6 months
D
10. Liver enzymes should be monitored regularly in patients with FMF 
treated with colchicine; if liver enzymes are elevated greater than 
twofold the upper limit of normal, colchicine should be reduced and 
the cause further investigated
D
11. In patients with decreased renal function, the risk of toxicity is very 
high, and therefore signs of colchicine toxicity, as well as CPK, should 
be carefully monitored and colchicine dose reduced accordingly
C
12. Colchicine toxicity is a serious complication and should be 
adequately suspected and prevented
C
13. When suspecting an attack, always consider other possible 
causes. During the attacks, continue the usual dose of colchicine 
and use NSAID
C
14. Colchicine should not be discontinued during conception, pregnancy, 
or lactation; current evidence does not justify amniocentesis
C
15. In general, men do not need to stop colchicine prior to conception; 
in the rare case of azoospermia or oligospermia proven to be 
related to colchicine, temporary dose reduction or discontinuation 
may be needed
C
16. Chronic arthritis in a patient with FMF might need additional 
medications, such as DMARDs, intra-articular steroid injections, or 
biologics
C
17. In protracted febrile myalgia, glucocorticoids lead to the resolution 
of symptoms; NSAID and IL-1-blockade might also be a treatment 
option; NSAIDs are suggested for the treatment of exertional leg pain
C
18. If a patient is stable with no attacks for more than 5 years and no 
elevated APR, dose reduction could be considered after expert 
consultation and with continued monitoring
D
APR, acute phase reactants; CPK, creatinine phosphokinase; DMARDs, disease-
modifying antirheumatic drugs; FMF, familial Mediterranean fever; IL-1, interleukin-1; 
NSAID, non-steroidal anti-inflammatory drugs.
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elucidated. However, we know that it prevents microtubule elon-
gation by binding to tubulin monomers and inhibiting polymer 
formation (64, 65). Thus, the link between pyrin and colchicine 
could be through the organization of actin cytoskeleton.
Previously, it was claimed that colchicine is an activator of 
RhoA (66). It binds to tubulin, depolymerizes microtubules and 
causes release of the RhoA activator guanine-nucleotide-exchange 
factor-H1, which is inactive when bound to microtubules (66). 
Park et al. demonstrated that colchicine inhibited the constitutive 
IL-1β release from bone-marrow-derived macrophages (BMDMs) 
of MefvV726A/V726A mice and C3-toxin-induced IL-1β release from 
primed BMDMs. In addition, colchicine inhibited IL-1β release 
from PBMCs of FMF patients (52). In the same lines, Van Gorp 
et al. demonstrated that microtubule-depolymerizing drugs selec-
tively inhibited the pyrin inflammasome (58). Thus, colchicine 
may be inhibiting pyrin inflammasome through RhoA activation 
by releasing RhoA activator from depolymerized microtubules.
Certain other pharmacological anti-inflammatory effects of 
colchicine have been enlightened such as preventing activation 
of neutrophils by forming β-tubulin–colchicine complexes and 
inhibiting the microtubule assembly and mitotic spindle forma-
tion, suppressing caspase-1 gene expression, and inhibiting the 
synthesis of tumor necrosis factor alpha (TNF-α) (65, 67–70).
It is suggested that colchicine should be started as soon as the 
patient is clinically diagnosed as having FMF. If the patient lacks 
clinical manifestations or subclinical inflammation, genetic diag-
nosis is not a precise indication to start treatment; however, these 
patients should be followed-up closely for clinical symptoms or 
signs of subclinical inflammation (17). In countries where amy-
loidosis has high frequency, the physician may consider treatment 
in these patients especially when the patient has homozygous 
M694V mutation, which is more frequently associated with the 
development of amyloidosis (9, 21, 71–77).
The optimal dosage of colchicine varies between studies and 
different clinical practices. The recommendation of the starting 
dose of colchicine in FMF is ≤0.5 mg/day for children <5 years of 
age; 0.5–1 mg/day for children 5–10 years of age; and 1–1.5 mg/day 
in children >10 years of age and in adults (in case tablet contains 
0.6 mg; ≤0.6 mg/day; 1.2 mg/day; and 1.8 mg/day, respectively) 
(17). Higher starting doses could be used in patients with high 
disease activity or disease complications such as amyloidosis (17). 
However, in most patients, it is started at the subtherapeutic dose of 
0.5 mg/day and adjusted according to disease activity and tolerance 
in the follow-up. While escalating colchicine dose in patients with 
active disease, monitoring C-reactive protein (CRP) and SAA, or 
both is required at least every 3 months (17). Both increase in attack 
frequency and presence of subclinical inflammation are indications 
to increase colchicine dose. The maximum dose is 2  mg/day in 
children and 3 mg/day in adults (14, 78). Dosing can be in single 
or divided doses. The dose can be divided to decrease side effects; 
however, a single daily dose may increase the compliance (17). 
Polat et al. have recently shown that using colchicine with either 
once- or twice-daily dosage provides similar clinical and laboratory 
improvement as well as the similar rate of drug side effect (79).
Colchicine treatment is lifelong in FMF. However, in EULAR 
recommendations, FMF experts recommend the consideration of 
colchicine dose reduction by an experienced center under certain 
circumstances with very careful and close follow-up (17).
Colchicine is a safe drug in the range of doses used for FMF 
treatment (80). The most common side effects of the drug and 
toxicity are also reviewed in the aforementioned recommenda-
tions. The most common side effect is gastrointestinal distur-
bance, which may be seen in up to 10% of patients during the 
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first month of the treatment (81, 82). It was shown that jejunal 
lactase, sucrase, and maltase activities decreased in patients on 
long-term colchicine treatment (83). In these patients, increased 
fecal excretion of starch, fat, and bile acids and decreased absorp-
tion of d-xylose and vitamin B12 occur, as well. These may be the 
explanation for diarrhea and lactose intolerance, and a sympto-
matic relief can be provided with a lactose-free diet (83, 84). Dose 
reduction may also improve the gastrointestinal symptoms (85). 
There are also some rare side effects of colchicine, such as vitamin 
B12 deficiency, reversible peripheral neuritis and myopathy, bone 
marrow suppression, and alopecia (86–89). In addition, some 
animal studies and case reports suggested its association with 
azoospermia (90, 91); however, this was only in very high doses. 
Thus, in general, men need not stop colchicine prior to concep-
tion (17). Colchicine use is safe during pregnancy and lactation, 
as well (92–94). However, it should be used cautiously in patients 
with impaired renal or hepatic functions (95).
Compliance with colchicine is very important for proper 
management of FMF. One study showed that proteinuria that 
is usually the first sign of renal amyloidosis, developed after a 
period of 9–11 years in 1.7% of 960 adult patients who properly 
used colchicine versus 49% in 54 patients who were not compli-
ant (96). There is a surprisingly high rate of incompliance with 
colchicine especially among adolescent patient (17). Thus, in 
the case of patients not responding to colchicine, the physician 
should keep in mind the possibility of incompliance. Overall, up 
to 5% of FMF patients may not respond to colchicine treatment 
and another 2–5% is colchicine intolerant (85).
Anti-IL-1 therapy seems to be a promising second-line therapy 
in refractory or intolerant patients. However, one should keep 
in mind that colchicine should be coadministered with biologic 
therapies since it may reduce the risk of amyloidosis (17). There 
are three types of anti-IL-1 agents in clinical use; anakinra, a 
recombinant homolog of the human IL-1 receptor (97); canaki-
numab, a fully human immunoglobulin G1 monoclonal antibody 
(98); and rilonacept, a dimeric Fc-fusion protein capturing IL-1 
(97); all administered subcutaneously.
The most recent systematic review of the literature (99) has 
yielded 24 case reports/series, 2 open-label prospective trials 
(100, 101), and 1 placebo-controlled prospective trial (102) on 
anti-IL-1 use in FMF. Eighteen reports were on treatment with 
anakinra (103–120), four on canakinumab (100, 101, 121, 122), 
four on patients treated with either anakinra or canakinumab 
(123–126), and the only placebo-controlled prospective trial 
was on treatment with rilonacept (102). A complete response 
to therapy was reported in 76.5% of patients on anakinra, and 
67.5% of patients on canakinumab treatment (99). In addition, 
IL-1 blockade can reverse proteinuria in patients with renal 
AA amyloidosis (99, 127). However, we do not know whether 
anti-IL-1 therapies could prevent amyloidosis. A new study on 
efficacy/safety of canakinumab in patients with hereditary peri-
odic fevers including FMF is also underway (http://ClinicalTrials.
gov identifier NCT02059291).
Anti-IL-1 drugs may be used “on demand” (starting at first 
symptom of attacks) in mevalonate kinase deficiency (128). We 
need further data on whether this would be an option for selected 
cases in FMF or on certain occasions.
Besides IL-1 blockade, FMF patients with chronic arthritis 
and/or sacroiliitis could benefit from disease-modifying anti-
rheumatic drugs or anti-TNF agents (129, 130).
Treatment of protracted febrile myalgia syndrome (PFMS) 
has also been addressed. PFMS is a very rare manifestation of 
FMF and is defined as severe, disabling myalgia of at least 5 days 
duration (108, 112). It is associated with fever, the presence of 
at least one M694V mutation, and elevated inflammatory mark-
ers while creatine kinase levels are usually normal (131, 132). 
Corticosteroid treatment is required to suppress symptoms (17, 
131, 133, 134). Non-steroidal anti-inflammatory drugs may also 
be beneficial (131). In addition, anakinra has been used success-
fully in two patients with PFMS associated with FMF (112).
Treatment in Heterozygotes
Familial Mediterranean fever is a clinical diagnosis, and we have 
many patients who are heterozygous for MEFV mutations. How 
patients with one mutation only can express the disease is still not 
clear (135). We give colchicine treatment to patients who express 
the typical FMF phenotype. However, some heterozygotes can 
sometimes “outgrow” the phenotype (30). Ben-Zvi et al. previ-
ously demonstrated that their patients (not using colchicine) 
experienced years of symptom-free interval where 22 out of these 
33 were heterozygotes (136).
The data on remission of the disease in heterozygotes are 
limited. Recently, we have reported our experience on heterozy-
gote patients with transient FMF clinic (7). We discontinued 
colchicine treatment in 22 heterozygote FMF patients who had 
an inflammation- and attack-free period for a long duration. The 
median follow-up after colchicine cessation was 22.5  months, 
and we restarted colchicine in only two patients because of the 
recurrence of attacks. However, after colchicine cessation, close 
follow-up is crucial every 3–6 months to evaluate whether they 
have recurrence of attacks or subclinical inflammation.
Refractory FMF and Outcome
There is no standard definition for refractory FMF patients. 
However, in the recent guideline, we stated that patients who 
continue to have ≥1 attacks per month despite receiving the 
maximally tolerated dose for ≥6  months might be considered 
non-responder or resistant to colchicine (17). Another issue is 
ongoing subclinical inflammation, which leaves the patients at 
risk of developing amyloidosis (17). In addition, in the case of 
AA amyloidosis, the FMF treatment should be intensified with 
biologics and maximal tolerated dose of colchicine (17).
There are mainly two tools to evaluate outcome and disease 
activity in FMF; FMF50 score and autoinflammatory disease 
activity index, respectively.
In FMF50, the items are percentage change in the frequency 
and duration of attacks, arthritis attacks, physician’s and patient’s/ 
parents’ global assessment of disease severity (0–10  cm visual 
analog scale; 10 the worst), and in ESR, CRP, or SAA level with the 
treatment (137). At least 50% improvement in five out of six cri-
teria by 3–6 months with no worsening in any one means FMF50 
response. It is noteworthy that compliance with the maximum 
dose of drug is essential for evaluating the patients with FMF50 
score.
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Autoinflammatory disease activity index is a disease activity 
assessment tool for AID including FMF, and it is composed of 
13 items: overall symptoms, nausea/vomiting, abdominal pain, 
diarrhea, chest pain, arthralgia or myalgia, swelling of the joints, 
headaches, eye manifestations, skin rash, and pain relief (138). 
Each item except pain relief is scored by the patients/parents for 
a total score of 0–34 in a single day and 0–1,054 in a month of 
31 days. A cutoff score of ≥9 discriminates active from inactive 
patients with a sensitivity of 89% and specificity of 92% (138).
There is also one recent tool for AID including FMF to quantify 
damage in patients and to compare disease outcomes in clinical 
studies; autoinflammatory disease damage index (ADDI) (139).
In ADDI, damage is defined as “persistent or irreversible change 
in structure or function that is present for at least 6 months” (139). 
ADDI contains 18 items, and these items are categorized by organ 
systems as follows: reproductive, renal/amyloidosis, develop-
mental, serosal, neurological, ears, ocular, and musculoskeletal. 
The renal/amyloidosis and neurological damage categories were 
assigned to have the highest number of points while serosal dam-
age got the lowest. This index provides a universal instrument to 
measure damage by chronic inflammation in FMF.
These tools could aid us to form a standard definition for 
refractory FMF patients and standardize the outcome measure-
ment in different studies.
UNSOlveD iSSUeS iN FMF
As we mentioned above in the relevant parts, there are still gaps 
in knowledge about the pathogenesis and treatment mechanisms 
in FMF. We need further research on the following:
 – the significance of the E148Q variant,
 – exact roles of modifier factors (microbiota, microRNAs, etc.) 
on disease pathogenesis, phenotypic expression, and severity 
of the disease,
 – the effects of mutant pyrin on apoptosis,
 – the exact reason for the self-limited and episodic nature of 
disease attacks,
 – whether anti-IL-1 treatment prevents amyloidosis,
 – the definition of colchicine resistance,
 – why certain rheumatic diseases are more common in 
heterozygotes, and why they sometimes express the disease 
phenotype,
 – the duration of treatment in heterozygous patients,
 – more biomarkers for secondary amyloidosis.
CONClUSiON
When the mutated protein for FMF was described 20  years 
ago, we thought that everything was resolved. However, this 
monogenic disease continues to be of interest to clinical and 
basic researchers. We still need to address the above questions 
and the cause of the phenotypic heterogeneity in this disease. On 
the other hand, the experts on FMF have worked on compiling 
recommendations to guide physicians in the diagnosis, manage-
ment, and treatment of FMF. It is hoped that these recommen-
dations may be of practical use while the work on solving the 
pathogenesis continue.
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